A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Bleeding

Interventions

BIOLOGICAL: Andexanet alfa (Gen 1 Process 2)
DRUG: Apixaban 5 MG
DRUG: Rivaroxaban 20 MG
DRUG: Enoxaparin sodium
DRUG: Edoxaban 60 MG
BIOLOGICAL: Andexanet alfa (Gen 2)
BIOLOGICAL: Andexanet alfa (Gen 1 Process 3)
DRUG: Apixaban 10 MG
DRUG: Rivaroxaban 10 MG

Sponsor

Portola Pharmaceuticals